Mednet Logo
Community

Does consolidation durvalumab increase the risk of pneumonitis in Stage III NSCLC?

Rate of pneumonitis was low in the PACIFIC trial but does it mirror the real world setting? We are seeing increased pneumonitis in our practice.
Community PollStarted

Does durvalumab significantly increase the risk of pneumonitis in Stage III NSCLC?

168 physicians have voted

Join Mednetto vote and see how they answered.

2 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Wexner Medical Center at The Ohio State University
Answered on

Given the heterogeneity of pneumonitis presentation, the presence of pre-checkpoint inhibitor chest/mediastinal irradiation (by definition in this trial), and the other risk factors often seen in this population (COPD/emphysema, current/past smoking history), it is a real challenge to decipher pulmo...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · Tufts University School of Medicine
Answered on

I’m seeing slightly higher incidence of pneumonitis in my practice than PACIFIC trial.

Join for free or sign in to see the full answer